Literature DB >> 748094

Serum glycoproteins in the liver diseases. V. Desialylated glycoproteins in chronic hepatitis.

T Arima, Y Motoyama, T Yamamoto, K Nagata, T Kondo, H Nagashima.   

Abstract

Serum desialylated glycoprotein level was tested for chronic hepatitic patients. The level was significantly elevated in patients with chronic aggressive hepatitis but not in chronic persistent hepatitis comparing to normal subjects. In chronic aggressive hepatitis, severe type (2B), serum desialylated glycoprotein levels were significantly enhanced but not in moderate type (2A) when compared to chronic persistent hepatitis. Sera taken serially from patients with chronic aggressive hepatitis, severe type (2B), demonstrated a slight correlation between circulating desialylated glycoprotein level and serum glutamic-pyruvic transaminase activity.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 748094     DOI： 10.1007/bf02774916

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN： 0435-1339


  7 in total

1.  Serum glycoproteins in the liver diseases. I. Studies on sialic acid-free glycoproteins-improved competitive binding assay of desialylated glycoprotein by rat liver plasma membrane.

Authors:  T Arima; Y Motoyama; K Nagata; T Kondo
Journal:  Gastroenterol Jpn       Date:  1976

2.  Serum glycoproteins in the liver diseases. III. Desialylated glycoproteins in the acute hepatitis.

Authors:  T Arima; Y Motoyama; T Yamamoto; K Nagata; T Kondo
Journal:  Gastroenterol Jpn       Date:  1977

3.  The binding of desialylated glycoproteins by plasma membranes of rat liver. Development of a quantitative inhibition assay.

Authors:  L Van Lenten; G Ashwell
Journal:  J Biol Chem       Date:  1972-07-25       Impact factor: 5.157

4.  A classification of chronic hepatitis.

Authors:  J De Groote; V J Desmet; P Gedigk; G Korb; H Popper; H Poulsen; P J Scheuer; M Schmid; H Thaler; E Uehlinger
Journal:  Lancet       Date:  1968-09-14       Impact factor: 79.321

Review 5.  Glycoproteins.

Authors:  R G Spiro
Journal:  Annu Rev Biochem       Date:  1970       Impact factor: 23.643

6.  Catabolism of desialylated ceruloplasmin in the liver.

Authors:  G Gregoriadis; A G Morell; I Sternlieb; I H Scheinberg
Journal:  J Biol Chem       Date:  1970-11-10       Impact factor: 5.157

7.  Measurement of circulating desialylated glycoproteins and correlation with hepatocellular damage.

Authors:  J S Marshall; A M Green; J Pensky; S Williams; A Zinn; D M Carlson
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808
  7 in total
  4 in total

1.  Ricinus communis agglutinin II-reactive glycoproteins from the ascites of patients with hepatocellular carcinoma and their use in enzyme-linked immunosorbent assay.

Authors:  M Fukushima; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1987-04

2.  Clinical application of the measurement of serum asialoglycoproteins to estimate residual liver function in patients with chronic liver diseases with or without hepatocellular carcinoma.

Authors:  T Sawamura; S Kawasato; M Tsuda; Y Naitoh; Y Shiozaki; Y Sameshima
Journal:  Gastroenterol Jpn       Date:  1985-06

3.  Serum glycoproteins in the liver diseases. VIII. Desialylated glycoproteins in the liver cirrhosis.

Authors:  T Arima
Journal:  Gastroenterol Jpn       Date:  1979-08

4.  Serum glycoproteins in the liver diseases. VI. The presence of desialylated glycoprotein binding activity in particulate fraction of human liver homogenate.

Authors:  T Arima; T Kondo; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1978
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.